Gaithersburg, MD, March 9, 2016 – MaxCyte®, Inc., the leader in driving the next generation of cellbased medicines with scalable, high-performance cell transfection systems will present data showing that flow electroporation technology can produce biologically active bispecific antibodies via transient expression in CHO cells. The data will be reported by Dr. Peer Heine, MaxCyte, at CHI’s Cancer Biotherapeutics Conference in London, UK on March 16, 2016. Specifically, the data will examine the expression, binding, and cytotoxicity of bispecific antibodies and tribodies transiently produced that specifically recruit immune effector cells to cancer cells. The data is the result of a collaboration with Dr. Matthias Peipp, PhD of Christian-Albrechts-University in Kiel, Germany.
Details of the MaxCyte presentation are as follows:
Speaker: Peer Heine, PhD, Field Application Scientist, MaxCyte
Title: High Expression of Bispecific Tandem scFvs and Tribody [(Her2)2X CD 16] in CHO Cells Transfected via Scalable Electroporation
Date: Wednesday March 16, 2016
Time: 12:20 PM
Location: DoubleTree by Hilton Hotel London – Docklands Riverside
Along with the podium presentation, MaxCyte will present a scientific poster with the data and have an exhibit booth with the MaxCyte STX® Scalable Transfection System. MaxCyte scientists will be available throughout the conference to provide technical details.
MaxCyte is the leader in driving the next generation of cell-based medicines. Flow electroporation, MaxCyte’s cell modification technology, is used for discovery, development, and manufacture of small molecule, biologic, and cell-based therapeutics. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of transfected cells for a broad array of applications.
For more information visit /